HUE027452T2 - Anti-clotting agents - Google Patents
Anti-clotting agents Download PDFInfo
- Publication number
- HUE027452T2 HUE027452T2 HUE12806229A HUE12806229A HUE027452T2 HU E027452 T2 HUE027452 T2 HU E027452T2 HU E12806229 A HUE12806229 A HU E12806229A HU E12806229 A HUE12806229 A HU E12806229A HU E027452 T2 HUE027452 T2 HU E027452T2
- Authority
- HU
- Hungary
- Prior art keywords
- dap
- compound
- subject
- factor
- anticoagulant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564559P | 2011-11-29 | 2011-11-29 | |
| US201261614292P | 2012-03-22 | 2012-03-22 | |
| US201261641698P | 2012-05-02 | 2012-05-02 | |
| US201261666291P | 2012-06-29 | 2012-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE027452T2 true HUE027452T2 (en) | 2016-09-28 |
Family
ID=47430065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12806229A HUE027452T2 (en) | 2011-11-29 | 2012-11-29 | Anti-clotting agents |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9522892B2 (https=) |
| EP (1) | EP2785700B1 (https=) |
| JP (1) | JP6134731B2 (https=) |
| KR (1) | KR101892330B1 (https=) |
| CN (1) | CN104080772B (https=) |
| AP (1) | AP2014007662A0 (https=) |
| AR (1) | AR089020A1 (https=) |
| AU (1) | AU2012345975B2 (https=) |
| BR (1) | BR112014012892B1 (https=) |
| CA (1) | CA2856540C (https=) |
| CL (1) | CL2014001399A1 (https=) |
| CO (1) | CO6990738A2 (https=) |
| CR (1) | CR20140310A (https=) |
| CY (1) | CY1117414T1 (https=) |
| DK (1) | DK2785700T3 (https=) |
| EA (1) | EA027603B1 (https=) |
| EC (1) | ECSP14006696A (https=) |
| ES (1) | ES2569674T3 (https=) |
| HR (1) | HRP20160513T1 (https=) |
| HU (1) | HUE027452T2 (https=) |
| IL (1) | IL232788B (https=) |
| ME (1) | ME02424B (https=) |
| MX (1) | MX349514B (https=) |
| PE (1) | PE20141295A1 (https=) |
| PH (1) | PH12014501176A1 (https=) |
| PL (1) | PL2785700T3 (https=) |
| PT (1) | PT2785700E (https=) |
| RS (1) | RS54738B1 (https=) |
| SG (1) | SG11201402713WA (https=) |
| SI (1) | SI2785700T1 (https=) |
| SM (1) | SMT201600161B (https=) |
| UA (1) | UA116336C2 (https=) |
| WO (1) | WO2013082210A1 (https=) |
| ZA (1) | ZA201404793B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999690B2 (en) | 2013-11-08 | 2018-06-19 | Perosphere Pharmaceuticals Inc. | Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| WO2019094959A1 (en) * | 2017-11-13 | 2019-05-16 | Fernandez Joss | Reconstitution of post mortem circulation, specialized methods and procedures |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
| US11915610B2 (en) | 2019-05-15 | 2024-02-27 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
| CN112010930B (zh) * | 2019-05-28 | 2022-08-02 | 首都医科大学 | Rgd修饰的五环哌嗪二酮及其制备和应用 |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| CN118684672A (zh) | 2023-03-24 | 2024-09-24 | 陕西麦科奥特科技有限公司 | 一种抗凝逆转剂及其制备方法和应用 |
| CN117624137A (zh) * | 2023-12-04 | 2024-03-01 | 中国药科大学 | 三嗪骨架小分子肝素逆转剂及其制备方法与用途 |
| US20250389737A1 (en) * | 2024-06-20 | 2025-12-25 | Instrumentation Laboratory Company | FACTOR Xa REAGENT |
| EP4667582A1 (en) * | 2024-06-20 | 2025-12-24 | Instrumentation Laboratory Company | Factor xa reagent |
| CN121622691A (zh) * | 2024-08-30 | 2026-03-10 | 陕西麦科奥特医药科技股份有限公司 | 使用抗凝逆转剂治疗抗凝剂导致的出血的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3678157A (en) * | 1968-10-23 | 1972-07-18 | Oreal | Hair treatment compositions containing polycondensable compounds |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6069232A (en) * | 1995-10-02 | 2000-05-30 | Hoechst Marion Roussel, Inc. | Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors |
| US6080852A (en) | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
| WO1998016547A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| JP2001519806A (ja) * | 1997-04-07 | 2001-10-23 | アクシス ファーマシューティカルズ，インコーポレイティド | セリンプロテアーゼ活性、特にトリプターゼ活性に関連する疾病を処理するための化合物及び組成物 |
| FR2781221B1 (fr) * | 1998-07-17 | 2000-10-13 | Lafon Labor | Piperazinones substituees en alpha |
| CA2348740A1 (en) * | 1998-12-23 | 2000-07-06 | Ruth R. Wexler | Thrombin or factor xa inhibitors |
| NZ514877A (en) | 1999-05-19 | 2004-10-29 | Pharmacia Corp | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| EP1377554A1 (en) * | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| CA2405684A1 (en) | 2000-04-17 | 2001-10-25 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| AU2001275857A1 (en) * | 2000-06-29 | 2002-01-14 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| EP1438292A1 (en) | 2001-10-03 | 2004-07-21 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| US20060148734A1 (en) * | 2002-03-27 | 2006-07-06 | Patrick Camilleri | Diaminoacid-aminoacid-polyamine based gemini surfactant compounds |
| JPWO2003099324A1 (ja) * | 2002-05-23 | 2005-09-22 | 中外製薬株式会社 | 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤 |
| GB0214122D0 (en) | 2002-06-19 | 2002-07-31 | Eastman Kodak Co | High contrast photographic element containing a polyhydrazide nucleating agent |
| SE0400014D0 (sv) * | 2004-01-08 | 2004-01-08 | Astrazeneca Ab | Heterocyclic derivatives |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| WO2008105441A1 (ja) * | 2007-02-27 | 2008-09-04 | Ajinomoto Co., Inc. | リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤 |
| EP2915564B1 (en) * | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
| GB2476643B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| PE20140964A1 (es) | 2011-03-30 | 2014-08-17 | Boehringer Ingelheim Int | Antidotos anticoagulantes |
-
2012
- 2012-11-29 US US13/688,442 patent/US9522892B2/en active Active
- 2012-11-29 SG SG11201402713WA patent/SG11201402713WA/en unknown
- 2012-11-29 CN CN201280060950.2A patent/CN104080772B/zh active Active
- 2012-11-29 EP EP12806229.6A patent/EP2785700B1/en active Active
- 2012-11-29 HR HRP20160513TT patent/HRP20160513T1/hr unknown
- 2012-11-29 JP JP2014544857A patent/JP6134731B2/ja active Active
- 2012-11-29 HU HUE12806229A patent/HUE027452T2/en unknown
- 2012-11-29 DK DK12806229.6T patent/DK2785700T3/en active
- 2012-11-29 ES ES12806229.6T patent/ES2569674T3/es active Active
- 2012-11-29 MX MX2014006349A patent/MX349514B/es active IP Right Grant
- 2012-11-29 CA CA2856540A patent/CA2856540C/en active Active
- 2012-11-29 EA EA201490823A patent/EA027603B1/ru unknown
- 2012-11-29 UA UAA201404997A patent/UA116336C2/uk unknown
- 2012-11-29 AP AP2014007662A patent/AP2014007662A0/xx unknown
- 2012-11-29 KR KR1020147016304A patent/KR101892330B1/ko active Active
- 2012-11-29 PE PE2014000763A patent/PE20141295A1/es active IP Right Grant
- 2012-11-29 PT PT128062296T patent/PT2785700E/pt unknown
- 2012-11-29 RS RS20160318A patent/RS54738B1/sr unknown
- 2012-11-29 SI SI201230558A patent/SI2785700T1/sl unknown
- 2012-11-29 PL PL12806229.6T patent/PL2785700T3/pl unknown
- 2012-11-29 AR ARP120104474A patent/AR089020A1/es active IP Right Grant
- 2012-11-29 WO PCT/US2012/066938 patent/WO2013082210A1/en not_active Ceased
- 2012-11-29 ME MEP-2016-95A patent/ME02424B/me unknown
- 2012-11-29 BR BR112014012892-8A patent/BR112014012892B1/pt active IP Right Grant
- 2012-11-29 AU AU2012345975A patent/AU2012345975B2/en active Active
-
2014
- 2014-05-26 PH PH12014501176A patent/PH12014501176A1/en unknown
- 2014-05-26 IL IL232788A patent/IL232788B/en active IP Right Grant
- 2014-05-27 CL CL2014001399A patent/CL2014001399A1/es unknown
- 2014-06-26 EC ECIEPI20146696A patent/ECSP14006696A/es unknown
- 2014-06-26 CR CR20140310A patent/CR20140310A/es unknown
- 2014-06-26 CO CO14137450A patent/CO6990738A2/es unknown
- 2014-06-27 ZA ZA2014/04793A patent/ZA201404793B/en unknown
-
2016
- 2016-04-25 CY CY20161100338T patent/CY1117414T1/el unknown
- 2016-06-08 SM SM201600161T patent/SMT201600161B/it unknown
- 2016-11-10 US US15/348,348 patent/US9877961B2/en active Active
-
2017
- 2017-10-06 US US15/726,497 patent/US20180207152A1/en not_active Abandoned
-
2020
- 2020-12-10 US US17/117,559 patent/US20210169874A1/en not_active Abandoned
-
2023
- 2023-12-15 US US18/541,391 patent/US20240366592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240366592A1 (en) | Anticoagulant reversal agents | |
| CN1078070C (zh) | 苯并噻吩衍生物在制备抑制凝血酶药物中的用途 | |
| JPH07509731A (ja) | トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド | |
| KR20010023364A (ko) | 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체 | |
| US20130296245A1 (en) | Prolinamiade derivatives as thrombin inhibitor, prepraration method and application thereof | |
| CN102325768B (zh) | 治疗疼痛和其他疾病的化合物和方法 | |
| US8530453B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
| TW200400971A (en) | Par-2-activating peptide derivative and pharmaceutical composition using the same | |
| OA16905A (en) | Anticoagulant reversal agents. | |
| HK1202858B (en) | Anticoagulant reversal agents | |
| EA007300B1 (ru) | Некоторые производные 1-(d-циклопропилглицинил)-4-(пиперидин-4-ил) пиперазина в качестве ингибиторов серинпротеазы фактора ха | |
| NZ625337B2 (en) | Anticoagulant reversal agents | |
| HK40094968B (zh) | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 | |
| HK40094968A (zh) | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 | |
| HK40123243A (zh) | 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法 | |
| US7084134B2 (en) | Thrombin inhibitors | |
| WO2005061549A1 (fr) | Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant | |
| Hens et al. | The Role of Kinetics in High Throughput Screening for Drugs |